Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 11/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.34 |
| ▸ | CDK9 | P50750 | 1/20 | 0.34 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL632786 | 1.00 | SIRT6 (0.47) | SIRT6LTA4HMTORGRM2CNR2 | |
| SCHEMBL633549 | 0.80 | LTA4H (0.47) | SIRT6LTA4HMTORGRM2CNR2 | |
| SCHEMBL632417 | 0.80 | LTA4H (0.47) | SIRT6LTA4HMTORGRM2CNR2 | |
| SCHEMBL632416 | 0.80 | LTA4H (0.47) | SIRT6LTA4HMTORGRM2CNR2 | |
| SCHEMBL633396 | 0.75 | CYP2A13 (0.54) | — | |
| SCHEMBL1421406 | 0.72 | LRRK2 (0.40) | SIRT6LTA4HMTORPIK3CA | |
| SCHEMBL1421372 | 0.72 | SIRT6 (0.39) | SIRT6LTA4HMTORGRM2CNR2 | |
| SCHEMBL1421368 | 0.72 | SIRT6 (0.39) | SIRT6LTA4HMTORGRM2CNR2 | |
| SCHEMBL1421405 | 0.72 | LRRK2 (0.40) | SIRT6LTA4HMTORPIK3CA | |
| SCHEMBL8805178 | 0.70 | LTA4H (0.56) | LTA4HMTORGRM2CNR2PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102459252-A | Imidazole-substituted pyrimidines for the treatment of glycogen synthase kinase 3 related diseases such as alzheimer's disease | ASTRAZENECA AB | 2012-05-16 | — | — | CN | disclosed |
| US-8178529-B2 | Imidazole substituted pyrimidines | ASTRAZENECA AB (SE) | 2012-05-15 | — | — | US | disclosed |
| US-20120077813-A1 | Imidazole Substituted Pyrimidines Useful in the Treatment of Glycogen Synthase Kinase-3 Related Disorders such as Alzheimer's Disease | ASTRAZENECA AB (SE) | 2012-03-29 | — | — | US | disclosed |
| EP-2419425-A1 | IMIDAZOLE SUBSTITUTED PYRIMIDINES USEFUL IN THE TREATMENT OF GLYCOGEN SYNTHASE KINASE 3 RELATED DISORDERS SUCH AS ALZHEIMER'S DISEASE | AstraZeneca AB (SE) | 2012-02-22 | — | — | EP | disclosed |
| WO-2010120237-A1 | IMIDAZOLE SUBSTITUTED PYRIMIDINES USEFUL IN THE TREATMENT OF GLYCOGEN SYNTHASE KINASE 3 RELATED DISORDERS SUCH AS ALZHEIMER'S DISEASE | ASTRAZENECA AB (SE) | 2010-10-21 | — | — | WO | disclosed |
| US-20100267723-A1 | Imidazole Substituted Pyrimidines | ASTRAZENECA AB (SE) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077813-A1 | Imidazole Substituted Pyrimidines Useful in the Treatment of Glycogen Synthase Kinase-3 Related Disorders such as Alzheimer's Disease | GSK3A, GSK3B, PYGB | SIRT6 654/4885LTA4H 4384/4885MTOR 215/4885 |
| US-20100267723-A1 | Imidazole Substituted Pyrimidines | GSK3B, GSK3A, STK3 | SIRT6 417/4885LTA4H 4574/4885MTOR 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.